CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Covax-19™Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D002318 Cardiovascular Diseases NIH 0.21

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0001626 Abnormality of the cardiovascular system HPO 0.21

There is one clinical trial.

Clinical Trials

1 A Phase I Trial of a Therapeutic Vaccine (Covax-19™) in SARS-CoV-2 Infected Patients

GC004 is a Phase I trial to evaluate the safety and the immune responses of a therapeutic vaccine in SARS-CoV-2 infected patients. Covid-19 confirmed patients with mild or no symptoms will be enrolled sequentially into low dose and high dose groups. Following the vaccination subjects who received at least one vaccination will be followed for safety through week 26.

NCT04428073 COVID Biological: Covax-19™

Primary Outcomes

Description: Frequency and severity of adverse events, laboratory abnormalities, local and systemic reactogenicity, signs and symptoms after vaccinations.

Measure: To evaluate the safety of a therapeutic Covid-19 vaccine in participants by measuring the severity of local and systemic adverse events and laboratory abnormalities.

Time: 26 weeks

Secondary Outcomes

Description: Magnitude of IFN-γ producing CD8+ T cells to SARS-CoV-2 nucleocapsid peptides pools after vaccinations.

Measure: To evaluate the immunogenicity of a therapeutic Covid-19 vaccine in participants by measuring CD8+ T cells immune response

Time: 6 weeks

Description: Detection of SARS-CoV-2 by RT-PCR in respiratory tract specimens at week 0, 1, 2, 3, and 4.

Measure: Virologic response after vaccination

Time: 4 weeks

Description: Number of participants with moderate, severe or critical Covid-19 at week 6.

Measure: Clinical outcome and progression after vaccinations

Time: 6 weeks

No related HPO nodes (Using clinical trials)